C L Comella
Affiliation: Rush University Medical Center
- Treatment of restless legs syndromeCynthia L Comella
Movement Disorders Section, Department of Neurological Sciences, Rush Medical College, 1725 West Harrison Street, Suite 755, Chicago, IL, 60612, USA
Neurotherapeutics 11:177-87. 2014..Other agents, including the opioids and clonazepam do not have sufficient evidence to recommend them as treatment for RLS, although in an individual patient, they may provide benefit. ..
- Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphyCynthia L Comella
Department of Neurologic Sciences, Rush University Medical Center, 1725 W Harrison, Chicago, IL 60612, USA
Neurology 64:1450-1. 2005..The pergolide group (n = 10) worsened in actigraphic measures of sleep efficiency and sleep fragmentation vs the placebo group (n = 12). Side effects were more frequent in the pergolide group...
- Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystoniaC L Comella
Rush University Medical Center, Chicago, IL 60612, USA
Neurology 65:1423-9. 2005..To directly compare two serotypes of botulinum toxin (BoNTA and BoNTB) in cervical dystonia (CD) using a randomized, double-blind, parallel-arm study design...
- Treatment of cervical dystonia with botulinum toxinsC L Comella
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Eur J Neurol 13:16-20. 2006..Although many aspects of the technique of injection have not been adequately studied, general guidelines are available...
- Can families be screened for cervical dystonia using a telephone interview?Cynthia L Comella
Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Nat Clin Pract Neurol 2:20-1. 2006
- Sleep disturbances in Parkinson's diseaseCynthia L Comella
Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, Rush Medical College, 1725 West Harrison, Suite 755, Chicago, IL 60612, USA
Curr Neurol Neurosci Rep 3:173-80. 2003..Treatment is aimed toward improving night-time sleep and daytime drowsiness by addressing the causative factors...
- The treatment of cervical dystonia with botulinum toxinsC L Comella
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
J Neural Transm 115:579-83. 2008..However, it is likely that each brand and serotype may differ in immunogenic potential and occurrence of secondary unresponsiveness, an issue that is currently under active investigation...
- Restless legs syndrome: treatment with dopaminergic agentsCynthia L Comella
Department of Neurological Sciences, Rush Medical Center, Chicago, IL 60612, USA
Neurology 58:S87-92. 2002..Augmentation, although it may be associated with chronic agonist use, is usually mild and responsive to additional dosing. The direct dopamine receptor agonists have largely replaced levodopa as the most effective treatment for RLS...
- Sleep disorders in Parkinson's disease: an overviewCynthia L Comella
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 22:S367-73. 2007..Appropriate diagnosis of the sleep disturbance affecting a PD patient can lead to specific treatments that can consolidate nocturnal sleep and enhance daytime alertness...
- Botulinum toxins in neurological diseaseCynthia L Comella
Department of Neurological Sciences, Rush University Medical Center, 1725 West Harrison, Chicago, Illinois 60612, USA
Muscle Nerve 29:628-44. 2004..This review focuses on the pharmacology, electrophysiology, immunology, and application of botulinum toxin in selected neurological disorders...
- Menstrual-related changes in motoric function in women with Parkinson's diseaseK Kompoliti
Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, IL, USA
Neurology 55:1572-5. 2000..Although PD severity fluctuated during the study period, there was no significant correlation between the objective or subjective measures of parkinsonism and estrogen and progesterone levels...
- Muscle activation patterns in point-to-point and reversal movements in healthy, older subjects and in subjects with Parkinson's diseaseK D Pfann
The Department of Movement Science M C 194, University of Illinois at Chicago, 901 West Roosevelt Road, Chicago, IL 60608, USA
Exp Brain Res 157:67-78. 2004....
- High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson diseaseD E Vaillancourt
Department of Kinesiology and Nutrition, University of Illinois at Chicago, 1919 West Taylor, 650 AHSB, MC 994, Chicago, IL 60612, USA
Neurology 72:1378-84. 2009....
- Daytime sleepiness, agonist therapy, and driving in Parkinson diseaseCynthia L Comella
JAMA 287:509-11. 2002
- Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled studyDaniel Truong
The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
Mov Disord 20:783-91. 2005..These results confirm previous reports that Dysport (500 units) is safe, effective, and well-tolerated in patients with cervical dystonia...
- Association of daytime napping and Parkinsonian signs in Alzheimer's diseaseMargaret Park
Sleep Disorders Center, Rush University Medical Center, 710 South Paulina Street, JRB 6th Floor, Chicago, IL 60612, USA
Sleep Med 7:614-8. 2006..The purpose of this study was to determine whether more Parkinsonian motor signs exist in AD patients with more reported daytime napping compared to AD patients without daytime napping...
- Parkinson's disease--Part 2: Treatment of motor symptomsDaniel Weintraub
Department of Neurological Sciences, University of Pennsylvania, 330 S 9th St, Philadelphia, PA 19107, USA
Am J Manag Care 14:S49-58. 2008..Cost-effectiveness is a major consideration for managed care and is also analyzed for many available treatment options...
- Treatment of dystoniaJennifer G Goldman
Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 755, Chicago, IL 60612, USA
Clin Neuropharmacol 26:102-8. 2003..Studies in functional outcome and quality of life further support the importance of discovering safe and effective means to treat dystonia. An algorithmic approach may be useful to guide the physician along the various treatment choices...
- Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessmentDaniel Weintraub
University of Pennsylvania, Philadelphia, PA, USA
Am J Manag Care 14:S40-8. 2008..This article provides a brief review of the epidemiology, pathophysiology, clinical course, and burden of PD...
- Parkinson's disease--Part 3: Neuropsychiatric symptomsDaniel Weintraub
Department of Psychiatry and Neurology, University of Pennsylvania, 3615 Chestnut St, Philadelphia, PA 19104, USA
Am J Manag Care 14:S59-69. 2008..This article looks at useful screening measures to help clinicians recognize neuropsychiatric symptoms and offers suggestions for their effective treatment...
- Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin
Allergan, Inc, Global Drug Development, Irvine, California, USA
Mov Disord 23:1353-60. 2008..The current formulation of BoNTA rarely causes neutralizing antibody formation in CD subjects treated < or =4 years...
- Changes in the relationship between movement velocity and movement distance in primary focal hand dystoniaJaney Prodoehl
Department of Kinesiology and Nutrition, University of Illinois, Chicago, Chicago, IL 60612, USA
J Mot Behav 40:301-13. 2008..Underactivation of the 1st agonist burst appears to be the most likely reason to explain slowing...
- Force control and disease severity in Parkinson's diseaseJulie A Robichaud
Department of Physical Therapy, School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202, USA
Mov Disord 20:441-50. 2005..These measures provide objective quantification of the severity of motor impairment that can be used to investigate the efficacy of different interventions in individuals with PD...
- Effect of medication on EMG patterns in individuals with Parkinson's diseaseJulie A Robichaud
School of Kinesiology, University of Illinois at Chicago, Chicago, Illinois 60608, USA
Mov Disord 17:950-60. 2002..These results show that medication does not alter the temporal profile of EMG activation...
- Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous systemAlex Iranzo
Neurology Service, Hospital Clínic and Institut d Investigació Biomèdiques August Pi i Sunyer IDIBAPS, Barcelona, Spain
Mov Disord 22:S424-30. 2007....
- Rating scales for dystonia: a multicenter assessmentCynthia L Comella
Rush Presbyterian St Lukes Medical Center, Suite 755, 1725 West Harrison, Chicago, IL 60612
Mov Disord 18:303-12. 2003..Among scales, the total scores correlated (Pearson's r, 0.977-0.983). Overall, 74% of raters found the GDS the easiest to apply. The GDS with its simplicity and ease of application may be the most useful dystonia rating scale...
- Benefits and risks of pharmacological treatments for essential tremorKelly E Lyons
University of Kansas Medical Center, Kansas City, Kansas 66160, USA
Drug Saf 26:461-81. 2003..The use of medication and/or surgery can provide adequate tremor control in the majority of the patients...
- Strength deficits in primary focal hand dystoniaJaney Prodoehl
Department of Movement Sciences, College of Applied Health Sciences, University of Illinois at Chicago, Illinois 60612, USA
Mov Disord 21:18-27. 2006..The amount of co-contraction of antagonistic muscles was not significantly different between the two groups. These results are discussed in the context of dystonia as a disorder resulting from dysfunction of basal ganglia output...
- Greater impairment of extension movements as compared to flexion movements in Parkinson's diseaseJulie A Robichaud
Department of Human Movement Sciences M C 194, University of Illinois at Chicago, 901 West Roosevelt Road, Chicago, IL 60608, USA
Exp Brain Res 156:240-54. 2004..The results are consistent with the hypothesis that there is a differential impairment of neural activation of extensor muscles of the arm as compared to flexor muscles in subjects with PD...
- Restless legs syndromeIlia Itin
Rush University Medical Center, Section of Movement Disorders, 1725 West Harrison Street, Suite 755, Chicago, IL 60612, USA
Prim Care 32:435-48. 2005..The currently available medications are highly effective in treating RLS. The knowledge of clinical presentation and diagnostic features of RLS will empower the primary care practitioners to effectively treat their patients who have RLS...
- Rating scale for psychogenic movement disorders: scale development and clinimetric testingVanessa K Hinson
Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina, USA
Mov Disord 20:1592-7. 2005..The PMD scale adequately captures the complex movements of PMDs and can be used to assess PMDs and test the efficacy of intervention strategies...